Public & philanthropic financial contribution to the development of new drugs 2: EC-FP7 Health Projects

Duration: July 2020 – January 2021
Language: English

Publikation: Journalartikel

Background:
Following on from the previous project on public funding for research and development (R&D) of products (1), the analysis now focuses on EU research funding for the development of pharmaceuticals. 

Method:
All FP7 projects (2007-2013) on late-stage clinical research are analysed and case studies are used to shed light on public contributions to the development of concrete products, but also on publicly invested risk capital.

Results:
Schmidt L, Sehic O, Wild C (2021) EU FP7 research funding for an orphan drug (Orfadin®) and vaccine (Hep C) development: a success and a failure, submitted.

(1) Schmidt L, Wild C (2020) Assessing the public and philanthropic financial contribution to the development of new drugs: a bibliographic analysis. Science, Technology & Public Policy (STPP), 4 (1): 8-14.